CytRx
Corporation (NASDAQ: CYTR), a biopharmaceutical research and
development company specializing in oncology, today announced that
President and CEO Steven A. Kriegsman and Executive Vice President and
Chief Medical Officer Dr. Daniel Levitt will present at the Oppenheimer
24th Annual Healthcare Conference on Wednesday, December 11th
2013 at 4:30 p.m. Eastern time. The conference is being held December
10-11 at the Crowne Plaza Hotel in New York City.
Interested parties can access the audio webcast with slide presentation
at http://www.cytrx.com/investors/presentations.
An archived presentation will be available for 90 days.
About the Oppenheimer Healthcare Conference
Management teams from more than 100 companies will be presenting at the
Oppenheimer 24th Annual Healthcare Conference. The presenters
represent a broad spectrum of public and private healthcare companies
spanning all major sectors of the healthcare industry, including bio &
specialty pharmaceuticals; biotechnology; medical devices; healthcare
facilities; life science tools and diagnostics; healthcare information
technology and distribution, and healthcare providers and servicers.
About CytRx Corporation
CytRx Corporation is a biopharmaceutical research and development
company specializing in oncology. CytRx currently is focused on the
clinical development of aldoxorubicin (formerly known as INNO-206), its
improved version of the widely used chemotherapeutic agent doxorubicin.
CytRx is conducting a global Phase 2b clinical trial with aldoxorubicin
as a treatment for soft tissue sarcomas, has completed its Phase 1b/2
clinical trial primarily in the same indication and a Phase 1b study of
aldoxorubicin in combination with doxorubicin in patients with advanced
solid tumors, and has completed a Phase 1b pharmacokinetics clinical
trial in patients with metastatic solid tumors. CytRx plans to initiate
under a special protocol assessment a potential pivotal Phase 3 global
trial with aldoxorubicin as a therapy for patients with soft tissue
sarcomas whose tumors have progressed following treatment with
chemotherapy. CytRx also has initiated a Phase 2 clinical trial with
aldoxorubicin in patients with late-stage glioblastoma (brain cancer)
and plans to initiate a Phase 2 clinical trial for AIDS-related Kaposi’s
sarcoma. CytRx plans to expand its pipeline of oncology candidates based
on a linker platform technology that can be utilized with multiple
chemotherapeutic agents and may allow for greater concentration of drug
at tumor sites. CytRx also has rights to two additional drug candidates,
tamibarotene and bafetinib. CytRx completed its evaluation of bafetinib
in the ENABLE Phase 2 clinical trial in high-risk B-cell chronic
lymphocytic leukemia (B-CLL), and plans to seek a partner for further
development of bafetinib. For more information about CytRx Corporation,
visit www.cytrx.com.
Copyright Business Wire 2013